Clinical data from 14 randomized, double-blind studies were reviewed t
o compare the renal tolerance of non-ionic monomeric contrast agents (
iopamidol 300, iopromide 300, iohexol 300) with the non-ionic dimer io
trolan 280. A prospective study of iotrolan 280 versus iohexol 300 in
renally impaired patients was also evaluated. Differences between the
contrast agents were investigated using sub-group analysis of patients
with an increased risk of contrast-induced nephropathy. Both the pros
pective study and meta-analysis of previous studies indicate that iotr
olan 280 has less influence on renal function than the non-ionic monom
eric comparator agents.